The announcement of ZTlido's milestones, including its status as the top non-opioid pain medication and high patient satisfaction, is likely to positively impact Scilex's reputation and potentially its stock price. The treatment of over one million patients signifies widespread acceptance and use, which could translate into increased revenues and market share for Scilex. The high satisfaction rate further solidifies ZTlido's position in the market, potentially attracting more patients and healthcare providers.